

Idiopathic Pulmonary Fibrosis (IPF)

A Study to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Trial Status
Terminated

Trial Runs In
35 Countries

Trial Identifier
NCT04552899 2020-000791-38
WA42293

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04552899 2020-000791-38 WA42293
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=40 Years & <= 85 Years

Healthy Volunteers
No
